Abstract:Objective: To test the hypothesis that P-selectin plays a critical role in the development of endometriosis and that targeting P-selectin has therapeutic potential.Design: Prospective, randomized study.Setting: Academic facility.Animal(s): The first experiment used 24 each of female adult P-selectin knockout mice and C57BL/6 wild-type mice, and 96 male green fluorescent protein (GFP) transgenic mice. The second experiment used 16 female adult C57BL/6 mice.Intervention(s): In experiment 1, P-selectin knockout and wild-type mice alternately served as donors and recipients for the transplantation of endometrial tissue fragments into the peritoneal cavity to induce endometriosis. Two weeks later all four groups were each randomly divided into two equal-sized subgroups, receiving either green fluorescent protein-expressing platelets or saline infusion. In experiment 2, 2 weeks after the surgical induction of endometriosis, the mice were randomly divided into two groups, one receiving a 2-week treatment with a recombinant P-selectin protein and the other, non-immune IgG, both by intraperitoneal injection.Main Outcome Measure(s): Lesion size, hotplate latency, and immunohistochemistry analysis of platelet aggregation, angiogenesis, transforming growth factor beta 1, alpha-smooth muscle actin, collagen I, and the extent of macrophage infiltration in ectopic implants. The extent of fibrosis also was evaluated in experiment 2.Result(s): P-selectin deficiency significantly retarded the development of endometriosis in a mouse model of endometriosis. In addition, soluble P-selectin treatment markedly reduced the lesion size in mouse through decreased platelet aggregation and angiogenesis, improved general hyperalgesia, and reduced the extent of macrophages infiltration, resulting in reduced fibrotic tissue content.Conclusion(s): Targeting P-selectin-mediated platelet adhesion onto endometriotic lesions holds promise as a novel therapeutics for treating endometriosis. (C) 2015 by American Society for Reproductive Medicine.

[The Action of P38 MAP Kinase and Its Inhibitors on Endometriosis].

P2X3 Receptor Involvement in Endometriosis Pain Via ERK Signaling Pathway.

SB203580, a P38 Mitogen-Activated Protein Kinase Inhibitor, Suppresses the Development of Endometriosis by Down-Regulating Proinflammatory Cytokines and Proteolytic Factors in a Mouse Model.

Apoptosis and Endometriosis

Possible Involvement of Crosstalk Between Endometrial Cells and Mast Cells in the Development of Endometriosis Via CCL8/CCR1

C-Jun Nh2-Terminal Kinase and P38 Inhibition Suppresses Prostaglandin E2-Stimulated Aromatase and Estrogen Receptor Levels in Human Endometriosis

An Update on the Multifaceted Role of NF-kappaB in Endometriosis

MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?

Mitogen Activated Protein Kinases Signaling Pathway and Endometriosis

Recent Advance on P38 Mitogen-Activated Protein Kinases Inhibitors

Anti-inflammatory Cytokines in Endometriosis

Immune and endocrine regulation in endometriosis: what we know

Exosomes from the Uterine Cavity Mediate Immune Dysregulation via Inhibiting the JNK Signal Pathway in Endometriosis

Lipoxin A4 Suppresses IL-1β-Induced Cyclooxygenase-2 Expression Through Inhibition of p38 MAPk Activation in Endometriosis

Lipoxin A(4) Suppresses the Development of Endometriosis in an Alx Receptor-Dependent Manner Via the P38 Mapk Pathway

17Βe2 Promotes Cell Proliferation in Endometriosis by Decreasing PTEN Via NFκB-dependent Pathway

Differential Sensitivity of Human Endometrial Carcinoma Cells with Different PTEN Expression to Mitogen-Activated Protein Kinase Signaling Inhibits and Implications for Therapy

Hypoxia-inducible Factor-1Alpha: A Promising Therapeutic Target in Endometriosis.

Effect and Mechanisms of Kaempferol Against Endometriosis Based on Network Pharmacology and in Vitro Experiments

P38 Mapk Inhibits Breast Cancer Metastasis Through Regulation Of Stromal Expansion

P-selectin As a Potential Therapeutic Target for Endometriosis.